Drug Efficacy

Side Effects Regulatory Affairs Phase Trials Alcohol Consumption Weight Loss Weight Loss Studies

Novo Nordisk Partners with Septerna in $2.2 Billion Deal for Oral Obesity Therapies

The collaboration aims to develop four GPCR-targeted small-molecule treatments, diversifying Novo Nordisk’s portfolio amid rising competition from Eli Lilly.

9 ARTICLES

4mo ago

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock

10 ARTICLES

7mo ago

Novo Nordisk Launches Wegovy in France Without Reimbursement